title: YKL-40: may be use as a new inflammatory biomarker in obstructive sleep apnea syndrome?
abstract: BACKGROUND
  YKL-40 [chitinase-3 like-1 (CHI3L1)] is a glycoprotein, has been implicated in inflammation, endothelial dysfunction, tissue remodelling and it is accepted as a noninvasive prognostic biomarker for inflammation. In this study, we aimed to underline usability of serum YKL-40 as an inflammatory biomarker in patients with obstructive sleep apnea syndrome (OSAS).
  
  
  METHODS
  Two groups OSAS patients [Group I: Mild-moderate OSAS, n:43; median apnea-hypopnea index: AHI, /hour:18], Group II: Severe OSAS, n: 25; AHI:41.6] and healthy control group [n:25, AHI: 3.6] were included in the study. Serum YKL-40 level was tested in serum samples taken after polysomnography in OSAS patients and control group. In addition, the association of serum YKL-40 level with age, body mass index and polysomnografic parameters were analyzed in the OSAS patient groups.
  
  
  RESULTS
  Median serum YKL-40 level was 20.30 ng/mL (range 8.01-73 ng/mL) in mild-moderate OSAS patients, and 22.58 ng/mL (9.17-99 ng/mL in severe OSAS patients, 18 ng/mL (range 7.36-88 ng/mL) in control group (p< 0.05). Serum YKL-40 level was found to be correlated with AHI in patient with mild-moderate OSAS patients (p< 0.05) and serum YKL-40 level was found to be correlated with age, total hypopnea time (minutes) in severe OSAS patients (p< 0.05). There was no relationship serum YKL-40 level with other studied variables (p> 0.05).
  
  
  CONCLUSIONS
  At the end of this study, we found that serum YKL-40 level increase with severity of OSAS. The findings suggest that YKL-40 may be a useful biomarker for inflammation in patients with OSAS.
authors.affiliation: Clinic of Chest Diseases, Diskapi Yildirim Beyazit Training and Research Hospital, Ankara, Turkey. akcalis@hotmail.com.
authors.forename: Serap
authors.initials: S
authors.lastname: Duru
authors.forename: Gülbahar
authors.initials: G
authors.lastname: Yüce
authors.forename: Hikmet
authors.initials: H
authors.lastname: Fırat
authors.forename: Bengül
authors.initials: B
authors.lastname: Şimşek
authors.forename: Fatma
authors.initials: F
authors.lastname: Uçar
authors.forename: Sadık
authors.initials: S
authors.lastname: Ardıç
authors.forename: Emine Bahar
authors.initials: EB
authors.lastname: Kurt
mesh_terms: D054392:Adipokines / Q000097:blood*; D000328:Adult; D000367:Age Factors; D000428:Alcohol Drinking / Q000009:adverse effects; D015415:Biomarkers / Q000097:blood; D015992:Body Mass Index; D016022:Case-Control Studies; D000071451:Chitinase-3-Like Protein 1; D005260:Female; D005500:Follow-Up Studies; D006801:Humans; D007249:Inflammation / Q000097:blood / Q000150:complications / Q000175:diagnosis; D037102:Lectins / Q000097:blood*; D008297:Male; D008875:Middle Aged; D017286:Polysomnography; D012720:Severity of Illness Index; D020181:Sleep Apnea, Obstructive / Q000097:blood / Q000150:complications / Q000175:diagnosis*; D012907:Smoking / Q000009:adverse effects
chemical_list: D054392:Adipokines; D015415:Biomarkers; C084533:CHI3L1 protein, human; D000071451:Chitinase-3-Like Protein 1; D037102:Lectins